Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1

Trial ID: NCT04449198

Interventional - Phase 1 - Recruiting

The proposed study is designed to test the hypothesis that treatment of resveratrol for 12 weeks will improve both endothelin-B receptor (aim 1) and skeletal muscle mitochondrial function (aim 2) in people with type 1 diabetes.

Conditions

• Type 1 Diabetes

Interventions

• Resveratrol
• Placebo

Eligibility

Inclusion criteria

• Men and premenopausal women
• All races
• Clinical diagnosis of insulin-dependent type 1 diabetes (patients only)

Exclusion criteria

• Clinical diagnosis of hepatic, cardiovascular, or renal disease
• Uncontrolled diabetes (HbA1C \>12%)
• Diabetic complications (i.e. neuropathy)
• Uncontrolled hypertension (\>140/90 mm Hg on therapy)
• Pregnancy
• Use of vasoactive medications

Sponsor

Augusta University

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows